CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...